1. Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report
- Author
-
Miguel Ángel Sánchez-Chaparro, Carlota García-Arias, Pedro González-Santos, José Rioja, Pedro Valdivielso, [Valdivielso Felices,P, García-Arias,C, Sánchez-Chaparro,MA, González Santos,P] Lipids Unit, Department of Medicine, Hospital Virgen de la Victoria, Malaga and Department of Medicine & Dermatology, University of Malaga, Malaga, Spain. [Rioja,J] Department of Medicine & Dermatology, University of Málaga, Málaga, Spain., and This study was financed by a Ferrer-Novag 2007 grant.
- Subjects
Blood Glucose ,Male ,Very low-density lipoprotein ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Cardiovascular Agents::Antihypertensive Agents [Medical Subject Headings] ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Indoles ,Apolipoprotein B ,Hiperlipidemia Familiar Combinada ,Endocrinology, Diabetes and Metabolism ,Hyperlipidemia, Familial Combined ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Nutrition Therapy::Diet Therapy [Medical Subject Headings] ,Blood Pressure ,Apolipoproteína B-48 ,Diabetes Mellitus Tipo 2 ,Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,Chemicals and Drugs::Lipids::Fats::Dietary Fats::Dietary Fats, Unsaturated::Fatty Acids, Omega-3::Eicosapentaenoic Acid [Medical Subject Headings] ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Fatty Acids, Monounsaturated ,chemistry.chemical_compound ,Study Protocol ,Terapia Combinada ,Hyperlipidemia ,Chemicals and Drugs::Pharmaceutical Preparations::Drug Combinations [Medical Subject Headings] ,Ácidos Grasos Monoinsaturados ,Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Indoles [Medical Subject Headings] ,Hypolipidemic Agents ,biology ,Hipolipemiantes ,Middle Aged ,Presión Arterial ,Eicosapentaenoic acid ,Combined Modality Therapy ,Lipids ,Drug Combinations ,Eicosapentaenoic Acid ,Docosahexaenoic acid ,Lípidos ,Hypertension ,Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids, Unsaturated::Fatty Acids, Monounsaturated [Medical Subject Headings] ,Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2 [Medical Subject Headings] ,Hemoglobina A Glucosilada ,Female ,lipids (amino acids, peptides, and proteins) ,Ácidos Docosahexaenoicos ,Cardiology and Cardiovascular Medicine ,medicine.drug ,medicine.medical_specialty ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Combined Modality Therapy [Medical Subject Headings] ,Diet, Reducing ,Docosahexaenoic Acids ,Check Tags::Male [Medical Subject Headings] ,Chemicals and Drugs::Lipids::Lipoproteins::Apolipoproteins::Apolipoproteins B::Apolipoprotein B-48 [Medical Subject Headings] ,Chemicals and Drugs::Lipids [Medical Subject Headings] ,Antihipertensivos ,Ácido Eicosapentaenoico ,Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension [Medical Subject Headings] ,Glucemia ,Chemicals and Drugs::Carbohydrates::Glycosides::Hemoglobin A, Glycosylated [Medical Subject Headings] ,Internal medicine ,Hipertensión ,Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Hemodynamics::Blood Pressure [Medical Subject Headings] ,medicine ,Humans ,Hypoglycemic Agents ,Fluvastatin ,Antihypertensive Agents ,Omacor ,Glycated Hemoglobin ,Triglyceride ,Cholesterol ,business.industry ,Chemicals and Drugs::Lipids::Fats::Dietary Fats::Dietary Fats, Unsaturated::Fatty Acids, Omega-3::Docosahexaenoic Acids [Medical Subject Headings] ,medicine.disease ,Combinación de Medicamentos ,Endocrinology ,chemistry ,Check Tags::Female [Medical Subject Headings] ,Diabetes Mellitus, Type 2 ,lcsh:RC666-701 ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antimetabolites::Hypolipidemic Agents [Medical Subject Headings] ,biology.protein ,Dietoterapia ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings] ,business ,Apolipoprotein B-48 ,Diseases::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Metabolism, Inborn Errors::Lipid Metabolism, Inborn Errors::Hyperlipidemia, Familial Combined [Medical Subject Headings] ,Chemicals and Drugs::Carbohydrates::Monosaccharides::Hexoses::Glucose::Blood Glucose [Medical Subject Headings] - Abstract
Backgorund Mixed hyperlipidemia is common in patients with diabetes. Statins, the choice drugs, are effective at reducing lipoproteins that contain apolipoprotein B100, but they fail to exert good control over intestinal lipoproteins, which have an atherogenic potential. We describe the effect of prescription omega 3 fatty acids on the intestinal lipoproteins in patients with type 2 diabetes who were already receiving fluvastatin 80 mg per day. Methods Patients with type 2 diabetes and mixed hyperlipidemia were recruited. Fasting lipid profile was taken when patients were treated with diet, diet plus 80 mg of fluvastatin and diet plus fluvastatin 80 mg and 4 g of prescription omega 3 fatty acids. The intestinal lipoproteins were quantified by the fasting concentration of apolipoprotein B48 using a commercial ELISA. Results The addition of 4 g of prescription omega 3 was followed by significant reductions in the levels of triglycerides, VLDL triglycerides and the triglyceride/HDL cholesterol ratio, and an increase in HDL cholesterol (P < 0.05). Fluvastatin induced a reduction of 26% in B100 (P < 0.05) and 14% in B48 (NS). However, the addition of omega 3 fatty acids enhanced this reduction to 32% in B100 (NS) and up to 36% in B48 (P < 0.05). Conclusion Our preliminary findings therefore suggest an additional benefit on postprandial atherogenic particles when omega 3 fatty acids are added to standard treatment with fluvastatin.
- Published
- 2009